- •Diabetic Retinopathy
- •Preface
- •Contents
- •Contributors
- •Nonproliferative Diabetic Retinopathy
- •Nonproliferative Diabetic Retinopathy
- •Inflammatory Mechanisms
- •Microaneurysms
- •Vascular Permeability
- •Capillary Closure
- •Classification Of Nonproliferative Retinopathy
- •Macular Edema
- •Risk Factors For Progression Of Retinopathy
- •Severity of Retinopathy
- •Glycemic Control
- •The Diabetes Control and Complications Trial
- •Epidemiology of Diabetes Interventions and Complications Trial
- •The United Kingdom Prospective Diabetes Study
- •Hypertension
- •The United Kingdom Prospective Diabetes Study
- •Appropriate Blood Pressure Control in Diabetes Trials
- •Elevated Serum Lipid Levels
- •Pregnancy and Diabetic Retinopathy
- •Other Systemic Risk Factors
- •Management Of Nonproliferative Diabetic Retinopathy
- •Photocoagulation
- •Scatter Photocoagulation for Nonproliferative Diabetic Retinopathy
- •Scatter Photocoagulation for Proliferative Retinopathy
- •Focal Photocoagulation for Diabetic Macular Edema
- •Other Treatment of Diabetic Macular Edema
- •Medical Therapy
- •Aspirin And Antiplatelet Treatments
- •Aldose Reductase Inhibitors
- •Other Medical Treatments
- •Summary
- •Acknowledgment
- •References
- •Proliferative Diabetic Retinopathy
- •Development and Natural History
- •Histopathology and Early Development
- •Proliferation and Regression of New Vessels
- •Contraction of the Vitreous and Fibrovascular Proliferations
- •Retinal Distortion and Detachment
- •Burned-Out Proliferative Diabetic Retinopathy
- •Systemic Associations
- •Proliferative Diabetic Retinopathy and Glycemic Control
- •Other Risk Factors for Proliferative Diabetic Retinopathy
- •Rubeosis Iridis
- •Anterior Hyaloidal Fibrovascular Proliferation
- •Management of Proliferative Diabetic Retinopathy
- •Pituitary Ablation
- •Photocoagulation
- •Randomized Clinical Trials of Laser Photocoagulation
- •The Diabetic Retinopathy Study
- •Risks and Benefits Photocoagulation In The Drs
- •The Early Treatment Diabetic Retinopathy Study
- •Indications For Photocoagulation of Pdr
- •PRP and Macular Edema
- •PRP Treatment Techniques
- •Vitrectomy for PDR
- •Pharmacologic Treatment of PDR
- •Acknowledgment
- •References
- •Brief Historical Background
- •The Wesdr
- •Prevalence of Diabetic Retinopathy
- •Incidence of Diabetic Retinopathy
- •Diabetic Retinopathy in African American and Hispanic Whites
- •Native Americans and Asian Americans
- •Age and Puberty
- •Genetic and Familial Factors
- •Modifiable Risk Factors
- •Hyperglycemia
- •Clinical Trials of Intensive Treatment of Glycemia
- •Diabetes Control and Complications Trial
- •The United Kingdom Diabetes Prospective Study (UKPDS)
- •Hypertension
- •Lipids
- •Subclinical and Clinical Diabetic Nephropathy
- •Microalbuminuria and Diabetic Retinopathy
- •Gross Proteinuria and Retinopathy
- •Diabetic Retinopathy as a Risk Indicator of Subclinical Nephropathy
- •Other Risk Factors For Retinopathy
- •Smoking and Drinking
- •Body Mass Index and Physical Activity
- •Hormone and Reproductive Exposures in Women
- •Prevalence and Incidence of Visual Impairment
- •Conclusions
- •Acknowledgments
- •References
- •Introduction
- •Fluorescein Angiography
- •Properties
- •Side Effects
- •Normal Fluorescein Angiography
- •Terminology
- •Fluorescein Angiography in the Evaluation of Diabetic Retinopathy
- •Fluorescein Angiography in the Evaluation of Diabetic Macular Edema
- •Optical Coherence Tomography
- •Low-Coherence Interferometry
- •OCT Image Interpretation
- •OCT Technology Development
- •The Role of OCT in Diabetic Macular Edema
- •Morphologic Patterns of Diabetic Macular Edema
- •Clinical Applications of OCT in Diabetic Macular Edema
- •Conclusions
- •References
- •Diabetic primates
- •Type of Diabetes
- •Histopathology and Rate of Development of the Retinopathy
- •Therapies Studied in this Model
- •Advantages and Disadvantages of the Model
- •Diabetic dogs
- •Type of Diabetes
- •Histopathology and Rate of Development of Retinopathy
- •Therapies Studied in this Model
- •Advantages and Disadvantages of the Model
- •Diabetic cats
- •Type of Diabetes
- •Histopathology and Rate of Development of Retinopathy
- •Therapies Studied in this Model
- •Advantages and Disadvantages of the Model
- •Diabetic rats
- •Type of Diabetes
- •Type 1 diabetes
- •Type 2 diabetes
- •Histopathology and Rate of Development of Retinopathy
- •Vascular disease
- •Neuronal disease
- •Therapies or Gene Modifications Studied in this Model
- •Advantages and Disadvantages of the Model
- •Diabetic mice
- •Type of Diabetes
- •Type 1 diabetes
- •Type 2 diabetes
- •Histopathology and Rate of Development of Retinopathy
- •Vascular disease
- •Neural disease
- •Therapies or Gene Modifications Studied in this Model
- •Advantages and Disadvantages of the Model
- •Other Rodents
- •Galactose Feeding
- •Nondiabetic Models in Which Growth Factors are Altered
- •VEGF overexpression
- •IGF overexpression
- •PDGF-B-deficient mice
- •Oxygen-Induced Retinopathy
- •Sympathectomy
- •Retinal Ischemia–Reperfusion
- •Summary
- •References
- •Introduction
- •Biochemistry and Genetics of The Polyol Pathway
- •Aldose Reductase
- •The Aldose Reductase Enzyme
- •The Aldose Reductase Gene
- •Polymorphisms of the AR Gene
- •Sorbitol Dehydrogenase
- •The Sorbitol Dehydrogenase Enzyme
- •The Sorbitol Dehydrogenase Gene
- •Ar Polymorphisms and Risk of Diabetic Retinopathy
- •Sdh Polymorphisms and Diabetic Retinopathy
- •Ar Overexpression
- •Sdh Overexpression
- •Ar “Knockout” Mice
- •Sdh-Deficient Mice
- •Osmotic Stress
- •Oxidative Stress
- •Activation of Protein Kinase C
- •Generation of AGE Precursors
- •Proinflammatory Events and Apoptosis
- •Ari Structures and Properties
- •Effects of Aris in Experimental Diabetic Retinopathy
- •The Polyol Pathway in Human Diabetic Retinopathy
- •The Sorbinil Trial
- •Perspective and Needs
- •Rationale for Defining the Pathogenic Role of the Polyol Pathway
- •Needs to be Met to Arrive at Anti-Polyol Pathway Therapy
- •References
- •Introduction to Diabetic Retinopathy
- •Biochemistry of Age Formation
- •Pathogenic Role of Ages In Diabetic Retinopathy
- •AGEs and Clinical Correlation of Diabetic Retinopathy
- •AGE Accumulation in the Eye
- •Effect of AGEs on Retinal Cells
- •RAGE in Diabetic Retinopathy
- •Other AGE Receptors in Diabetic Retinopathy
- •Anti-Age Strategies For Diabetic Retinopathy
- •Conclusion
- •References
- •Introduction
- •Dag-Pkc Pathway
- •Diabetes and Retinal Blood Flow
- •Basement Membrane and Ecm Changes
- •Vascular Permeability and Angiogenesis
- •Conclusions
- •References
- •Sources of Oxidative Stress in The Diabetic Retina
- •Overview
- •Mitochondrial Electron Transport Chain (ETC)
- •Advanced Glycation End (AGE) Product Formation
- •Cyclo-oxygenase (COX)
- •Flux Through Aldose Reductase (AR) Pathway
- •Activation of Protein Kinase C (PKC)
- •Endothelial NO Synthase (eNOS)
- •Inducible NOS (iNOS)
- •NADPH Oxidase
- •Antioxidants in Diabetic Retinopathy
- •Overview
- •Glutathione (GSH)
- •Superoxide Dismutase (SOD)
- •Catalase
- •Effects of Oxidative Stress in The Diabetic Retina
- •Overview
- •Growth Factors and Cytokines
- •Cytoxicity
- •Therapeutic Strategies For Reducing Oxidative Stress
- •Overview
- •Antioxidants
- •PKC Inhibitors
- •Inhibitors of the Renin-Angiotensin System
- •Inhibitors of the Polyol Pathway
- •HMG-CoA Reductase Inhibitors (Statins)
- •PEDF
- •Cannabinoids
- •Cyclo-oxygenase-2 (COX-2) Inhibitors
- •References
- •Pericyte Loss in the Diabetic Retina
- •Introduction
- •Origin and Differentiation
- •Morphology and Distribution
- •Identification
- •Function
- •Contractility
- •Role in Vessel Formation and Stabilization
- •Loss In Diabetic Retinopathy
- •Rats
- •Mice
- •Chinese Hamster
- •Animal Models Mimicking Retinal Pericyte Loss
- •Pdgf-B-Pdgf-Ssr
- •Angiopoietin-Tie
- •Vegf-Vegfr2
- •Mechanisms of Loss
- •Biochemical Pathways
- •Aldose Reductase
- •Age Formation
- •Modification of Ldl
- •Loss Through Active Elimination
- •Capillary Dropout in Diabetic Retinopathy
- •Diabetic Retinopathy
- •Methods to Measure and Detect Capillary Dropout
- •Models to Study Retinal Capillary Dropout in Diabetes
- •Potential Mechanisms For Capillary Dropout
- •Capillary Cell Apoptosis
- •Proinflammatory Changes/Leukostasis
- •Microthrombosis/Platelet Aggregation
- •Consequences of Capillary Dropout
- •Macular Ischemia
- •Neovascularization
- •Macular Edema
- •Acknowledgments
- •References
- •Neuroglial Dysfunction in Diabetic Retinopathy
- •The Neurons of The Retina
- •The Glial Cells of The Retina
- •Diabetes Reduces Retinal Function
- •Diabetes Induces Neurodegeneration in The Retina
- •Neuroinflammation in Diabetic Retinopathy
- •Historical Perspective on Diabetic Retinopathy
- •Neuroglial Dysfunction in Diabetic Retinopathy.
- •References
- •Introduction
- •Inflammatory Cells Promote and Regulate The Development of Ischemic Ocular Neovascularization
- •VEGF as a Proinflammatory Factor in Diabetic Retinopathy
- •VEGF164/165 as a Proinflammatory Cytokine
- •Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- •Corticosteroids
- •Anti-VEGF Agents
- •Pegaptanib
- •Ranibizumab and Bevacizumab
- •Conclusions
- •Acknowledgment
- •References
- •Glia-Endothelial Interaction
- •Specialized Retinal Vessels Control Flux into Neural Tissue
- •Overview of Tight Junction Proteins
- •Claudins Confer Tight Junction Barrier Properties
- •Occludin Regulates Barrier Properties
- •Alterations in Occludin in Diabetic Retinopathy
- •Ve-Cadherin and Diabetic Retinopathy
- •Permeability in Diabetic Retinopathy
- •Summary and Conclusions
- •References
- •Introduction
- •Stages of Angiogenesis
- •Vascular Endothelial Growth Factor
- •Regulation of Vegf Expression in The Retina
- •Regulation of VEGF in Proliferative Diabetic Retinopathy
- •Regulation of VEGF in Nonproliferative Diabetic Retinopathy
- •Basic Vegf Biology
- •Receptors
- •Vegf’S Multiple Actions on Retinal Endothelial Cells
- •Main Signaling Pathways
- •Other Actions of Vegf
- •Proinflammatory Effects of VEGF
- •VEGF and Retinal Neuronal Development
- •VEGF and Neuroprotection
- •Modulation of Vegf Action By Other Growth Factors
- •Conclusion
- •References
- •Insulin-Like Growth Factor
- •Basic Fibroblast Growth Factor
- •Angiopoietin
- •Erythropoietin
- •Hepatocyte Growth Factor
- •Tumor Necrosis Factor
- •Extracellular Proteinases
- •The Urokinase Plasminogen Activator System (uPA/uPAR System)
- •Proteinases in Retinal Neovascularization
- •Integrins
- •Endogenous Inhibitors of Neovascularization
- •Pigment Epithelium Derived Growth Factor
- •Angiostatin and Endostatin
- •Thrombospondin-1
- •Tissue Inhibitor of Matrix Metalloproteinases
- •Clinical Implications
- •Acknowledgments
- •References
- •Introduction
- •Pathogenesis
- •Vascular Endothelial Growth Factor (Vegf)
- •Vegf in Physiological and Pathological Angiogenesis
- •Vegf in Ocular Neovascularization
- •Vegf and Diabetic Retinopathy
- •Clinical Application of Anti-VEGF Drugs
- •Pegaptanib
- •Bevacizumab
- •Ranibizumab
- •Use of Anti-VEGF Therapies in Diabetic Retinopathy
- •Safety
- •Clinical Experience with Bevacizumab in Diabetic Retinopathy
- •Ranibizumab in Diabetic Macular Edema
- •Effect on Foveal Thickness and Macular Volume
- •Effect on Visual Acuity
- •Summary
- •References
- •Introduction
- •Pkc Inhibition With Ruboxistaurin
- •Early Clinical Trials With Rbx
- •Rbx and Progression of Diabetic Retinopathy
- •Ongoing Trials With Rbx
- •Rbx and Other, Nonocular Complications of Diabetes
- •Safety Profile of Rbx
- •Clinical Status of Rbx
- •Conclusions
- •References
- •The Role of Intravitreal Steroids in the Management of Diabetic Retinopathy
- •Clinical Efficacy
- •Safety
- •Pharmacology
- •Pharmacokinetics
- •Combination With Laser Treatment
- •Clinical Guidelines
- •Macular Edema Caused by Focal Parafoveal Leak
- •Widespread Heavy Diffuse Leak
- •Macular Edema and High-Risk Proliferative Retinopathy
- •Macular Edema Prior to Cataract Surgery
- •Juxtafoveal Hard Exudate With Heavy Leak
- •Control of Systemic Risk Factors
- •The Future of Intravitreal Steroid Therapy
- •References
- •Overview
- •Introduction and Historical Perspective
- •Growth Hormone and Diabetic Retinopathy
- •The IGF-1 System and Retinopathy
- •The Role of SST in Diabetic Retinopathy
- •Rationale for the Clinical use of Octreotide
- •Clinical evidence for sst as a therapeutic for pdr
- •Potential Reasons for Mixed Success in Clinical Trials
- •Future Direction: Sst Analogs in Combination Therapy
- •Conclusion
- •Acknowledgements
- •Introduction
- •Diabetic Retinopathy and Mortality
- •Diabetic Retinopathy and Cerebrovascular Disease
- •Diabetic Retinopathy and Heart Disease
- •Diabetic Retinopathy, Nephropathy, and Neuropathy
- •Conclusion
- •References
- •Name Index
11 Capillary Dropout in Diabetic Retinopathy
Renu A. Kowluru and Pooi-See Chan
CONTENTS
DIABETIC RETINOPATHY
ORGANIZATION, STRUCTURE, COMPOSITION, AND FUNCTION OF
RETINAL CAPILLARIES
PATHOLOGY AND CLINICAL MANIFESTATION OF CAPILLARY
DROPOUT IN DIABETIC RETINOPATHY
METHODS TO MEASURE AND DETECT CAPILLARY DROPOUT
MODELS TO STUDY RETINAL CAPILLARY DROPOUT IN DIABETES
POTENTIAL MECHANISMS FOR CAPILLARY DROPOUT
DIABETES-INDUCED BIOCHEMICAL PATHWAYS PROMOTING
CAPILLARY DROPOUT
CONSEQUENCES OF CAPILLARY DROPOUT
THERAPEUTIC APPROACHES TO PREVENT/RETARD CAPILLARY
DROPOUT IN DIABETES
REFERENCES
ABSTRACT
Capillary dropout is a critical process in diabetic retinopathy, resulting in ischemia, release of angiogenic growth factors, and sight-threatening retinal neovascularization.
It is essential to gain a greater understanding of this process in order to develop improved treatments for diabetic retinopathy. This chapter will review the organization, structure, and cellular composition of retinal capillaries. The histopathologic and clinical manifestations of capillary dropout in diabetic retinopathy will be discussed. Methods for detecting capillary dropout and experimental models for studying this phenomenon will be presented. Potential mechanisms for capillary dropout as well as contributory biochemical pathways will be discussed. Finally, the clinical consequences of capillary dropout will be summarized, highlighting the critical importance of this process in the pathophysiology of diabetic retinopathy.
From: Contemporary Diabetes: Diabetic Retinopathy
Edited by: E. Duh © Humana Press, Totowa, NJ
265
266 |
Kowluru et al. |
Key Words: Diabetic retinopathy, Capillary dropout, Acellular capillaries, Endothelial cell, Apoptosis
DIABETIC RETINOPATHY
Retinopathy, one of the major microvascular complications of diabetes, is the leading cause of blindness throughout the world in the 20–74 year age group. Its effects on the quality of life and loss of productivity for patients and their families are a leading socioeconomic burden on the community. Diabetic retinopathy is a slowly progressing lifelong disease that is exacerbated by high blood pressure, puberty, or pregnancy (1, 2). It affects both type I and type II diabetic patients. With the incidence of type II diabetes increasing worldwide and the age of onset decreasing dramatically, retinopathy is becoming a major global concern.
Retinopathy is a multifactorial complication of diabetes, and sustained hyperglycemia is considered a major cause of slow and cumulative damage to the small blood vessels in the retina (3, 4). The major determinants for the progression of diabetic retinopathy are duration of diabetes and the degree of glycemic control maintained over the years (5). During the initial stages, background retinopathy, small blood vessels may begin to bleed and leak fluid into the surrounding retinal tissue, but the disease remains asymptomatic. As retinal blood vessels continue to get damaged, portions of the retinal microcirculation begin to close down causing the retina to become ischemic. Capillary dropout is a critical process in diabetic retinopathy, resulting in ischemia, release of angiogenic growth factors, and sight-threatening retinal neovascularization (6). As a result, it is necessary to gain a greater understanding of this process in order to develop improved treatments for diabetic retinopathy.
ORGANIZATION, STRUCTURE, COMPOSITION, AND FUNCTION
OF RETINAL CAPILLARIES
In order to appreciate how capillaries are damaged in the retina, it is imperative that we have a better understanding of the organization and structure of this delicate but complex tissue. The retina has four major types of cells: vascular (pericytes and endothelial cells), macroglial cells (Muller cells and astrocytes), neurons (photoreceptors, bipolar cells, amacrine and ganglion cells), and microglia (which act as phagocytes). The retinal vessels are highly organized and have three layers of microvessels: a superficial layer in the ganglion cell layer, an intermediate layer in the inner plexiform layer, and a deep layer in the outer plexiform layer (Fig. 1) (7). In humans, the retinal vessels occupy the inner half of the neural retina. The retinal vasculature is separated from the surrounding neural components by the cytoplasm of Muller cells and glial cells. Blood vessels extend outward from the optic disc in all directions spreading their network across the retina, stopping short of the periphery, and also sparing the fovea. Although the arrangement of retinal vessels is unique for each human, the larger blood vessels, in general, occupy the innermost portion of the retina while smaller blood vessels, the capillaries, are found between the nerve fiber and inner nuclear layers (8). The diameter of the capillary network varies in different parts of the retina; the outer mesh ranges from 15 to 130 m while the superficial network averages about 65 m (9). The
Capillary Dropout in Diabetic Retinopathy |
267 |
Fig. 1. Organization and structure of retina showing different cell types. The highly organized retinal vessels have three layers of microvessels: a superficial layer in the ganglion cell layer, an intermediate layer in the inner plexiform layer, and a deep layer in the outer plexiform layer. The retinal vasculature is separated from the surrounding neural components by the cytoplasm of Muller cells and glial cells.
Fig. 2. Retinal capillary structure showing the organization of capillary cells on the basement membrane.
retinal capillary wall is lined by a single layer of endothelial cells encompassed by a basement membrane and surrounded by pericytes (Fig. 2) (10).
The basement membrane, a connective tissue sheath, surrounds the capillaries. It is a definite membrane with a fibrillar structure and has uniform thickness. The retinal capillary basement membrane is mainly composed of collagen types IV and V, laminin and heparan sulfate proteoglycan core protein (11). Its function is to structurally support the endothelial cells and pericytes and also to anchor retinal vessels to adjacent tissues.
268 |
Kowluru et al. |
Fig. 3. Cross section of a capillary demonstrating tight junctions in between endothelial cells and coverage by pericytes.
The vascular endothelial cells and pericytes lie on the basement membrane (Fig. 3). Endothelial cells are the predominant cells initially but 3 months after birth, pericytes are observed on the microvessels (12). Fusion of membranes between endothelial cells forms the tight junctional complexes (7,13). These junctions are largely responsible for the blood–retinal barrier that impedes the outward passage of circulating proteins (14). The integrity of the blood–retinal barrier is essential for normal visual function, and the disruption of this barrier is seen in diabetic retinopathy and other ocular diseases. Under normal conditions, the vascular endothelium also acts as a barrier to the trafficking of leukocytes into the retina. The blood–retinal barrier serves as a selective partition between the retina and the blood circulation enabling the retina to regulate its environment in response to varying metabolic demands. In diabetes the blood–retinal barrier breaks down and permeability to larger molecules, including albumin, is increased (15).
The endothelium is surrounded by pericytes that exchange paracrine signals through a shared basement membrane (16). These cells have nuclei which often appear to protrude from the capillary wall, and have long and slender processes which envelop the wall and overlap neighboring cells (17). They are spaced regularly along the retinal capillary and are in direct contact with endothelial cells. Pericytes are not present on the newly formed capillary beds, but are seen only within the maturing vascular network (7). Pericytes provide structural support, help in contraction and regulate the endothelial cells. Contractility of pericytes confers the ability to regulate retinal vascular tone and blood flow (18).
PATHOLOGY AND CLINICAL MANIFESTATION OF CAPILLARY
DROPOUT IN DIABETIC RETINOPATHY
Capillaries function to provide nutrients (glucose, fatty acids, and amino acids) to the retina and to metabolically exchange respiratory gases, and also to remove waste products from the retina in order to maintain retinal homeostasis (19). This fundamental role of the capillaries requires proper functioning of the components of the capillaries. Capillary dropout is characterized by the loss of capillary components that results ultimately in the degeneration or obliteration of capillaries.
In the early stage or background retinopathy, the selective loss of pericytes from the retinal capillaries is consistently shown to occur before any histopathological signs can
